- Home
- KRON
KRON
Kronos Bio Inc.
as 07-26-2024 4:00pm EST
Kronos Bio Inc is a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel cancer therapeutics designed to transform patient outcomes through a precision medicine plan by targeting dysregulated transcription. The company operates in one business segment, the development of biopharmaceutical products.
| Founded: | 2017 | Country: | United States |
| Employees: | N/A | City: | SAN MATEO |
| Market Cap: | 44.4M | IPO Year: | 2020 |
| Target Price: | $4.13 | AVG Volume (30 days): | 258.0K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 2 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.99 | EPS Growth: | N/A |
| 52 Week Low/High: | $0.69 - $2.09 | Next Earning Date: | 08-06-2024 |
| Revenue: | $7,587,000 | Revenue Growth: | 521.38% |
| Revenue Growth (this year): | 23.93% | Revenue Growth (next year): | -57.19% |
Stock Insider Trading Activity of Kronos Bio Inc. (KRON)
| Name | Ticker | Relationship | Date | Transaction | Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| BISCHOFBERGER NORBERT W | KRON | PRESIDENT & CEO | Jun 27 '24 | Buy | $1.25 | 204,670 | $254,957.42 | 10,802,138 | SEC Form 4 |
| BISCHOFBERGER NORBERT W | KRON | PRESIDENT & CEO | Jun 27 '24 | Buy | $1.17 | 410,848 | $478,843.34 | 10,597,468 | SEC Form 4 |
| BISCHOFBERGER NORBERT W | KRON | PRESIDENT & CEO | Jun 10 '24 | Buy | $1.24 | 881,913 | $1,096,041.48 | 7,375,616 | SEC Form 4 |
| BISCHOFBERGER NORBERT W | KRON | PRESIDENT & CEO | Jun 10 '24 | Buy | $1.09 | 744,308 | $814,570.68 | 6,493,703 | SEC Form 4 |
| BISCHOFBERGER NORBERT W | KRON | PRESIDENT & CEO | Jun 10 '24 | Buy | $0.88 | 1,378,901 | $1,208,468.84 | 5,749,395 | SEC Form 4 |
| Lin Charles Y | KRON | SR VP, RESEARCH & DEVELOPMENT | Feb 21 '24 | Sell | $1.05 | 12,036 | $12,684.74 | 234,603 | SEC Form 4 |
| Olek Elizabeth A | KRON | SR VP, CLINICAL SCIENCE | Feb 21 '24 | Sell | $1.05 | 7,368 | $7,765.14 | 193,275 | SEC Form 4 |
| Frisbee Allison | KRON | SR VP, CORP OPERATIONS & LEGAL | Feb 21 '24 | Sell | $1.05 | 12,105 | $12,757.46 | 204,510 | SEC Form 4 |
| DiMartino Jorge | KRON | Chief Medical Officer & VP | Jan 4 '24 | Sell | $1.18 | 12,009 | $14,213.85 | 315,246 | SEC Form 4 |
| Dinsmore Christopher | KRON | Chief Scientific Officer | Jan 4 '24 | Sell | $1.18 | 7,366 | $8,718.40 | 260,969 | SEC Form 4 |
| Kosacz Barbara | KRON | COO & General Counsel | Jan 4 '24 | Sell | $1.18 | 10,676 | $12,636.11 | 928,966 | SEC Form 4 |
| DiMartino Jorge | KRON | Chief Medical Officer & VP | Dec 12 '23 | Sell | $1.31 | 17,367 | $22,663.93 | 327,255 | SEC Form 4 |
| Dinsmore Christopher | KRON | Chief Scientific Officer | Dec 12 '23 | Sell | $1.31 | 10,032 | $13,091.76 | 268,335 | SEC Form 4 |
Latest Kronos Bio Inc. News
KRON Breaking Stock News: Dive into KRON Ticker-Specific Updates for Smart Investing
MT Newswires
3 days ago
Kronos Bio Says 1st Patient Dosed With KB-0742 in Expansion Group Focused on Platinum-Resistant Ovarian Cancer
GlobeNewswire
3 days ago
Kronos Bio Announces First Patient Dosed with KB-0742 in an Expansion Cohort Focused on Platinum-Resistant High-Grade Serous Ovarian Cancer
Simply Wall St.
a month ago
Shareholders May Be More Conservative With Kronos Bio, Inc.'s (NASDAQ:KRON) CEO Compensation For Now
Simply Wall St.
a month ago
Insider Spends US$3.1m Buying More Shares In Kronos Bio
Business Wire
2 months ago
Engelhart Commodities Trading Partners Agrees to Acquire Trailstone, Strengthening Commitment to the Energy Transition
GlobeNewswire
2 months ago
Delfi Meedia, a subsidiary of AS Ekspress Grupp to acquire business operations of Eesti Koolitus- ja Konverentsikeskus
GlobeNewswire
2 months ago
Share buy-back programme - week 23
Simply Wall St.
2 months ago
Do Scientex Berhad's (KLSE:SCIENTX) Earnings Warrant Your Attention?
Compare KRON vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "KRON Kronos Bio Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.